Okhravi Narciss, Morris Ainsley, Kok Howe Sen, Menezo Victor, Dowler Jonathan G F, Hykin Phillip G, Lightman Sue
Medical Retina and Uveitis Service, Moorfields Eye Hospital, London, United Kingdom.
J Cataract Refract Surg. 2007 Jul;33(7):1278-83. doi: 10.1016/j.jcrs.2007.03.030.
To report the outcomes of cataract extraction with intraoperative intravitreal triamcinolone (IVTA) in eyes with a history of posterior uveitis.
Moorfields Eye Hospital Uveitis Service, London, United Kingdom.
Nineteen eyes of 17 patients with posterior uveitis thought to require systemic corticosteroid prophylaxis for cataract surgery were included. The use of systemic corticosteroids at the time of surgery would have been problematic in 7 of the patients, who had a history of systemic hypertension. Three of the 7 patients were also diabetic. All patients were not happy about using oral corticosteroids.
Median visual acuity 1 day after surgery was 20/40 (range 20/20 to counting fingers). At final follow-up (mean 25.2 months; range 7 to 41 months), 17 eyes (89.5%) eyes achieved visual acuity of 20/40 or better; 2 eyes failed to achieve a final visual acuity of 20/40 or better, 1 as a result of optic atrophy and the other as a result of macular edema. No patient lost acuity and no eye developed macular edema within 4 months of surgery. Intraocular pressure elevation occurred after surgery in 3 eyes; all were controlled by topical medication that was discontinued after 3 months. One patient developed severe intraocular inflammation after surgery that resolved with intensive topical corticosteroid therapy within 1 week.
Cataract extraction by phacoemulsification with concurrent IVTA appears a useful treatment option. Targeted delivery of corticosteroid is achieved without the risks of systemic corticosteroid prophylaxis. The incidence of postoperative macular edema was markedly reduced. Levels of visual acuity after cataract surgery, similar to those in eyes without uveitis, were achieved in eyes with posterior uveitis.
报告在有后葡萄膜炎病史的眼中进行白内障摘除联合术中玻璃体内注射曲安奈德(IVTA)的结果。
英国伦敦摩尔菲尔德眼科医院葡萄膜炎服务中心。
纳入17例后葡萄膜炎患者的19只眼,这些患者被认为白内障手术需要全身使用皮质类固醇预防。手术时使用全身皮质类固醇对7例有全身高血压病史的患者存在问题。这7例患者中有3例也是糖尿病患者。所有患者都不愿意使用口服皮质类固醇。
术后1天的中位视力为20/40(范围20/20至数指)。在最终随访时(平均25.2个月;范围7至41个月),17只眼(89.5%)视力达到20/40或更好;2只眼最终视力未达到20/40或更好,1只眼是由于视神经萎缩,另1只眼是由于黄斑水肿。术后4个月内没有患者视力下降,也没有眼发生黄斑水肿。3只眼术后出现眼压升高;均通过局部用药控制,3个月后停药。1例患者术后发生严重眼内炎症,在1周内通过强化局部皮质类固醇治疗消退。
白内障超声乳化摘除联合IVTA似乎是一种有用的治疗选择。实现了皮质类固醇的靶向给药,而没有全身皮质类固醇预防的风险。术后黄斑水肿的发生率明显降低。后葡萄膜炎患者白内障手术后的视力水平与无葡萄膜炎的眼相似。